STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANAB
  4. [Form 4] ANAPTYSBIO, INC Insider Trading Activity

AnaptysBio (NASDAQ: ANAB) CFO logs RSU vesting and tax share sale

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

AnaptysBio, Inc. chief financial officer Dennis Mulroy reported the vesting of 8,292 restricted stock units on January 3, 2026, which converted into the same number of common shares at no cost upon settlement. Following this, his directly held common stock position increased to 17,693 shares.

On January 5, 2026, he sold 3,363 shares of AnaptysBio common stock at a price of $43.26 per share to cover tax withholding obligations related to the RSU vesting, described as a non-discretionary “sell to cover” transaction. After the sale, he directly held 14,330 shares of common stock and 16,585 RSUs, which continue to vest in 25% annual installments beginning January 3, 2025, subject to continued service.

Positive

  • None.

Negative

  • None.
Insider MULROY DENNIS
Role CHIEF FINANCIAL OFFICER
Sold 3,363 shs ($145K)
Type Security Shares Price Value
Sale Common Stock 3,363 $43.26 $145K
Exercise Restricted Stock Unit 8,292 $0.00 --
Exercise Common Stock 8,292 $0.00 --
Holdings After Transaction: Common Stock — 14,330 shares (Direct); Restricted Stock Unit — 16,585 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
MULROY DENNIS
(Last) (First) (Middle)
C/O ANAPTYSBIO, INC.
10770 WATERIDGE CIRCLE, SUITE 210
(Street)
SAN DIEGO CA 92121
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ANAPTYSBIO, INC [ ANAB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CHIEF FINANCIAL OFFICER
3. Date of Earliest Transaction (Month/Day/Year)
01/03/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/03/2026 M 8,292 A (1) 17,693 D
Common Stock 01/05/2026 S(2) 3,363 D $43.26 14,330 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 01/03/2026 M 8,292 (3) (3) Common Stock 8,292 $0 16,585 D
Explanation of Responses:
1. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration.
2. The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
3. The RSUs vests as to 25% of the total RSUs annually commencing on January 3, 2025 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
/s/ Eric Loumeau, Attorney-in-Fact 01/06/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did AnaptysBio (ANAB) disclose in this Form 4?

The filing reports that CFO Dennis Mulroy had 8,292 RSUs vest into common stock on January 3, 2026, and then sold 3,363 shares on January 5, 2026 to cover tax withholding obligations.

How many AnaptysBio (ANAB) shares did the CFO sell and at what price?

The CFO sold 3,363 shares of AnaptysBio common stock at $43.26 per share on January 5, 2026, as reported in the Form 4.

Was the AnaptysBio (ANAB) insider sale a discretionary transaction?

No. The footnote explains the sale was to cover tax withholding obligations tied to RSU vesting and was executed as a “sell to cover” transaction, not a discretionary sale by the reporting person.

How many AnaptysBio (ANAB) shares and RSUs does the CFO hold after these transactions?

After the reported transactions, the CFO directly holds 14,330 shares of common stock and 16,585 restricted stock units (RSUs), according to the Form 4.

What are the terms of the AnaptysBio (ANAB) RSU award mentioned in the Form 4?

Each RSU represents the right to receive 1 share of common stock for no consideration, and the award vests 25% annually beginning January 3, 2025, subject to the CFO’s continued service on each vesting date.

What role does the reporting person hold at AnaptysBio (ANAB)?

The reporting person, Dennis Mulroy, is identified as the Chief Financial Officer of AnaptysBio, Inc. in the Form 4.